ARTICLE | Finance

Obesity Approvable?

Glimmer of optimism for Vivus obesity drug; plans quick response to FDA

November 1, 2010 7:00 AM UTC

Investors finally got some heartening obesity news last week indicating that at least one of the trio of obesity compounds up for review by FDA has a glimmer of hope.

Vivus Inc. (NASDAQ:VVUS) received a complete response letter for its Qnexa phentermine/topiramate on Friday, sending shares up $1.62 (26%) to $7.75...